Caris Life Sciences (CAI) Cash from Operations (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Cash from Operations of 32876000.0 for Q1 2026, up 204.91% year-over-year from 10782276.54 in Q1 2025, and down 26.58% quarter-over-quarter from 44780000.0 in Q4 2025.
Powered by 
Analysis
Caris Life Sciences (CAI) Cash from Operations (2024 - 2026) Analysis & Trends
Caris Life Sciences' Cash from Operations history runs 3 years deep, the most recent figure standing at 32876000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 204.91% year-over-year to 32876000.0; the TTM figure through Mar 2026 stood at 147369000.0 (changed N/A YoY), while the FY2025 annual figure was 83155000.0, up 133.91% from the prior year.
- Cash from Operations for Q1 2026 stood at 32876000.0, down from 44780000.0 in the prior quarter.
- The five-year high for Cash from Operations was 62425000.0 in Q3 2025, with the low at 69427000.0 in Q3 2024.
- The 3-year median for Cash from Operations is 7288000.0 (2025), against an average of 1097571.43.
- Peak annual rise in Cash from Operations reached 215.05% in 2025, while the deepest fall reached 189.91% in 2025.
- Caris Life Sciences' Cash from Operations stood at 38921000.0 in 2024, then jumped by 215.05% to 44780000.0 in 2025, then dropped by 26.58% to 32876000.0 in 2026.
- Business Quant data shows CAI's Cash from Operations at 32876000.0 in Q1 2026, 44780000.0 in Q4 2025, and 62425000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Caris Life Sciences | 7.05 Bn | 6.25 Bn | 182.38 Mn | 28.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.48 Mn |
| Mar 31, 2026 | 32.88 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 62.43 Mn |
| Jun 30, 2025 | 7.29 Mn |
| Mar 31, 2025 | -31.34 Mn |
| Dec 31, 2024 | -38.92 Mn |
| Sep 30, 2024 | -69.43 Mn |